[Dopaminergic Progenitor Cell Transplantation for Parkinson's Disease Treatment].

Human fetal ventral mesencephalic tissue transplantation provided early evidence supporting the efficacy of cell replacement therapy for Parkinson's disease; however, major challenges, including ethical concerns and graft-induced dyskinesia (GID), were raised. Recently, clinical trials using dopaminergic progenitor cells derived from induced pluripotent or human embryonic stem cells have demonstrated favorable safety profiles, graft survival, and the apparent absence of GID. Well-designed clinical trials are required to confirm the safety and establish its definitive clinical efficacy.